文献速递水电解质与酸碱慢性肾脏病肾血管病与高血压

高钾血症的个体化治疗

Tailoring treatment of hyperkalemia.
PubMed 文献 · Nephrol Dial Transplant · 2019-01-01

本文综述高钾血症的个体化治疗策略。短期控制血钾的传统方法证据有限,新型口服药对非危及生命高钾血症结果积极但定位未明。高钾血症可能通过不当减量心血管药物(如RAAS抑制剂)长期影响心衰或肾衰竭患者结局,需根据患者状况调整治疗。

要点

  • 短期降钾传统策略证据有限且可能过度治疗
  • 新型口服药用于非危及生命高钾血症结果积极但角色未定
  • 高钾血症可致RAAS抑制剂不当减量而长期影响结局

核心结论

  • 高钾血症治疗需根据患者状况和条件进行短期和中期的个体化调整。
  • 识别治疗疗效和潜在副作用有助于量身定制治疗方案。

研究设计与样本

  • 综述,讨论高钾血症治疗如何根据患者状况和条件进行个体化。

主要发现

  • 大多数短期控制血钾的策略已使用数十年,但疗效和安全性证据仍低。
  • 新型口服治疗对非危及生命的高钾血症结果令人鼓舞,但其在治疗武器库中的作用仍不确定。
  • 越来越多证据表明高钾血症可能通过心血管药物(如RAAS抑制剂)减量或停用长期负面影响心衰或肾衰竭患者结局。

临床怎么用

  • 高钾血症治疗应避免过度治疗及短期副作用,并优先避免不必要住院或长期药物变更。
  • 对非危及生命高钾血症可考虑新型口服治疗,但需明确其定位。
  • 应关注高钾血症导致RAAS抑制剂不当减量对心衰或肾衰竭患者长期结局的负面影响。

局限性

  • 短期控制血钾策略的疗效和安全性证据仍低。
  • 新型口服治疗在高钾血症治疗中的角色仍不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hyperkalemia is a common electrolyte disorder that may be rapidly life-threatening because of its cardiac toxicity. Hyperkalemia risk factors are numerous and often combined in the same patient. Most of the strategies to control serum potassium level in the short term have been used for decades. However, evidence for their efficacy and safety remains low. Treatment of hyperkalemia remains challenging, poorly codified, with a risk of overtreatment, including short-term side effects, and with the priority of avoiding unnecessary hospital stays or chronic medication changes. Recently, new oral treatments have been proposed for non-life-threatening hyperkalemia, with encouraging results. Their role in the therapeutic arsenal remains uncertain. Finally, a growing body of evidence suggests that hyperkalemia might negatively impact outcomes in the long term in patients with chronic heart failure or kidney failure through underdosing or withholding of cardiovascular medication (e.g. renin-angiotensin-aldosterone system inhibitors). Recognition of efficacy and potential side effects of treatment may help in tailoring treatments to the patient's status and conditions. In this review we discuss how treatment of hyperkalemia could be tailored to the patient's conditions and status, both on the short and mid term.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Coutrot M, Dépret F, Legrand M, et al. Tailoring treatment of hyperkalemia. Nephrol Dial Transplant. 2019. PMID: 31800081. doi:10.1093/ndt/gfz220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。